Antibody libraries with maximized antibody developability characteristics

1. A method for preparing a human antibody light chain library, the method comprising:

deriving a single antibody light chain from the light chain of a single human antibody light chain variable domain gene or from a single human therapeutic antibody;

providing (a) a first plurality of nucleic acids encoding a population of naturally-occurring antibody light chain CDR1 fragments, (b) a second plurality of nucleic acids encoding a population of naturally-occurring antibody light chain CDR2 fragments, and/or (c) a third plurality of nucleic acids encoding a population of naturally-occurring antibody light chain CDR3 fragments, and

inserting the first plurality of nucleic acids, the second plurality of nucleic acids, and/or the third plurality of nucleic acids into the CDR1 region, the CDR2 region, and the CDR3 region, respectively, of an antibody light chain variable domain gene, thereby producing the human antibody light chain library;

wherein at least 90% of the population of naturally-occurring antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising one or more of:

(i) a glycosylation site,

(ii) a deamidation site,

(iii) an isomerization site,

(iv) unpaired cysteine,

(v) net charge greater than 1,

(vi) a tripeptide motif containing at least two aromatic residues,

(vii) a motif that promotes aggregation,

(viii) a poly specificity site;

(ix) a protease sensitive site,

(x) an integrin binding site,

(xi) a lysine glycation site,

(xii) a metal catalyzed fragmentation site,

(xiii) a poly specificity aggregation site; or

(xiv) a streptavidin binding motif;

wherein the human antibody light chain library has less than 10% non-functional light chain CDR1, less than 10% non-functional light chain CDR2, and less than 10% non-functional light chain CDR3 fragments;

wherein:

the glycosylation site of (i) comprises the motif NXS, NXT, or NXC, in which X represents any naturally-occurring amino acid residue except for proline;

the deamidation site of (ii) comprises the motif of NG, NS, NT, NN, NA, NH, ND, GNF, GNY, GNT, or GNG;

the isomerization site of (iii) comprises the motif of DT, DH, DS, DG, or DD;

the tripeptide of (vi) is HYF or HWH;

the motif that promotes aggregation of (vii) comprises the motif of FHW;

the polyspecificity site of (viii) comprises the motif GG, GGG, RR, VG, W, WV, WW, WWW, YY, or WXW, in which X represents any amino acid residue

the protease cleavage site of (ix) comprises the motif of DX, in which X is P, G, S, V, Y, F, Q, K, L, or D;

the integrin binding site of (x) comprises RGD, RYD, LDV, or KGD;

the lysine glycation site of (xi) comprises KE, EK, or ED;

the metal catalyzed fragmentation site of (xii) comprises the motif of HS, SH, KT, HXS, or SXH, in which X represents any amino acid residue;

the polyspecificity aggregation site of (xiii) comprises a motif of X1X2X3, wherein each of X1,X2, and X3 independently is selected from the group consisting of F, I, L, V, W and Y; or

the streptavidin binding motif of (xiv) comprises the motif HPQ, EPDW (SEQ ID NO: 117), PWXWL (SEQ ID NO: 118), in which X represents any amino acid residue, GDWVFI (SEQ ID NO: 119), or PWPWLG (SEQ ID NO: 120).

2. The method of claim 1 , wherein the population of antibody light chain CDR1 fragments, the population of antibody light chain CDR2 fragments, and/or the population of antibody light chain CDR3 fragments is free of members comprising at least two of (i)-(xiv).

3. The method of claim 1 , wherein the single human antibody light chain variable domain gene is selected from the group consisting of K1-12, K4-1, K2D-29, K3-11, K3-20, and L2-14.

4. The method of claim 1 , wherein the single human therapeutic antibody is selected from the group consisting of abrilumab, mepolizumab, crenezumab, necitumumab, anifrolumab, and evoculumab.

5. The method of claim 1 , wherein the single human therapeutic antibody is selected from the group consisting of abituzumab, adalimumab, alemtuzumab, alirocumab, bapineuzumab, benralizumab, brodalumab, canakinumab, certolizumab, clazakizumab, dacetuzumab, daclizumab, daratumumab, eculizumab, efalizumab, elotuzumab, epratuzumab, farletuzumab, fasinumab, ficlatuzumab, fletikumab, fresobmumab, fulranumab, gevokizumab, ibalizumab, lintuzumab, matuzumab, mavrilimumab, mogamubzumab, motavizumab, natalizumab, nivolumab, obinutuzumab, ofatumumab, olokizumab, omalizumab, onartuzumab, otelixizumab, otlertuzumab, palivizumab, panitumumab, panobacumab, pertuzumab, pinatuzumab, polatuzumab, radretumab, ramucirumab, reslizumab, romosozumab, sarilumab, secukinumab, sifalimumab, tabalumab, tigatuzumab, tildrakizumab, tocilizumab, tovetumab, trastuzumab, vedolizumab, veltuzumab, zalutumumab, and zanolimumab.

6. The method of claim 1 , wherein the light chain CDR1, CDR2, and CDR3 fragments are derived from naturally-occurring antibodies of a mammalian species.

7. The method of claim 6 , wherein the mammalian species is human.

8. The method of claim 1 , wherein the human antibody light chain library has less than 8% non-functional light chain CDR1, light chain CDR2, and light chain CDR3 fragments.

9. The method of claim 1 , wherein the human antibody light chain library has less than 5% non-functional light chain CDR1, light chain CDR2, and light chain CDR3 fragments.

10. The method of claim 5 , wherein the single human therapeutic antibody is trastuzumab.

11. The method of claim 1 , wherein the human antibody light chain library has at least 10 2 unique CDR1, CDR2, or CDR2 sequences.

12. The method of claim 1 , wherein the human antibody light chain library has at least 10 7 diversity.

13. The method of claim 1 , wherein the human antibody light chain library has at least 10 8 diversity.